AUTHORS
Yuemin Gong, PhD, WANG Shunqing2, Lina Zhang, MD3, Yingmei Li4, Taiwu Xiao, PhD5, Zunmin Zhu, MD6, Jianda Hu, PhD7, Yanhong Tong8, Yawen Zhang, PhD9, Ruiqing Zhou10, Guangsheng He11
AFFILIATIONS
1 The First Affiliated Hospital with Nanjing Medical University/Jiangsu Province Hospital, and Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, Nanjing, China
2 Guangzhou First People's Hospital, Guangzhou, China
3 Henan Cancer Hospital, Zhengzhou, China
4 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
5 Liaocheng People's Hospital, Liaocheng, China
6 Henan Provincial People's Hospital, Zhengzhou, China
7 The Second Affiliated Hospital of Fujian Medical University, Fujian, China
8 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
9 The First Affiliated Hospital with Nanjing Medical University/Jiangsu Province Hospital, and Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, Nanjing, China
10 Guangzhou First People's Hospital, Guangzhou, China
11 The First Affiliated Hospital with Nanjing Medical University/Jiangsu Province Hospital, and Jiangsu Province Engineering Research Center of Cell and Gene Therapy for Hematologic and Lymphoid Diseases, Nanjing, China
ABSTRACT
Introduction: Ciprocopan is a innovative, long half-life factor B inhibitor, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Results from the completed Phase III trial demonstrated that, in complement inhibitor-naïve patients with PNH, ciprocopan was superior to eculizumab in improving efficacy outcomes at week 24, with a favorable safety profile.
Aim: We further report data from the extension study (NCT06745622) on the efficacy and safety of ciprocopan 200mg once daily through 48 weeks of treatment in patients from the Phase III trial.
Methods: A total of 73 complement inhibitor-naïve Chinese adults with PNH were enrolled in the prior Phase III trial, with 37 assigned to the ciprocopan group and 36 to the eculizumab group. All patients had baseline hemoglobin <10 g/dL, lactate dehydrogenase (LDH) >1.5×the upper limit of normal (ULN), and no laboratory evidence of bone marrow failure. Upon completion of the initial 24-week treatment period of the Phase III trial, eligible patients entered the extension study to receive ciprocopan (patients in the eculizumab group were switched to ciprocopan after the 24-week period). Efficacy and safety assessments were conducted at scheduled visits. The primary endpoint of the extension study was the incidence and severity of adverse events (AEs). Secondary endpoints included the proportion of patients achieving hemoglobin ≥12 g/dL without red blood cell (RBC) transfusion at 24-week intervals during the treatment period, and the change from baseline in hemoglobin; the proportion of patients who remained transfusion-free at each visit; the proportion of patients experiencing breakthrough hemolysis (BTH) and major adverse vascular events (MAVEs).
Results: All 73 patients who completed the Phase III trial entered the extension study and received a cumulative 48 weeks of treatment. At week 48, the proportion of patients achieving hemoglobin ≥12 g/dL was 75.7% (28/37) in the ciprocopan group and 77.8% (28/36) in the eculizumab-to-ciprocopan group, with the latter showing a marked increase from 8.3% during the 24-week eculizumab treatment period. Mean baseline hemoglobin value was 7.6 g/dL in the ciprocopan group and 7.3 g/dL in the eculizumab-to-ciprocopan group; at week 48, mean hemoglobin reached 13.5 g/dL and 13.7 g/dL, corresponding to mean increases from baseline of 6.0 g/dL and 6.4 g/dL, respectively. The eculizumab-to-ciprocopan group demonstrated substantial improvement compared with the 24-week mean hemoglobin value of 10.0 g/dL. The proportion of patients who remained transfusion-free was 94.6% (35/37) in the ciprocopan group at week 48, and 97.2% (35/36) in the eculizumab-to-ciprocopan group during the extension period (weeks 24 to 48), indicating decreased transfusion requirements after switching to ciprocopan. Over the 48-week treatment period, BTH occurred in 2 of 73 patients (2.7%) receiving ciprocopan, with no MAVEs reported. The most common drug-related AE was headache (ciprocopan group: 18.9% [7/37]; eculizumab-to-ciprocopan group: 5.6% [2/36]). Serious AEs were reported in 1 patient (2.7%) in the ciprocopan group and 3 patients (8.3%) in the eculizumab-to-ciprocopan group, of which 1 case of pneumonia and 1 case of pelvic infection were considered drug-related. No AEs led to treatment discontinuation or dose reduction.
Conclusions: Ciprocopan as monotherapy maintenance treatment in patients with PNH provides sustained improvement in hemoglobin levels and reduces transfusion requirements. The long-term safety profile remains favorable, with no new safety signals identified.
DISCLOSURES
Guangsheng He: No relevant conflicts of interest to declare.